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Purpose: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of
death worldwide. Impaired lung function is associated with heightened risk for death,
cardiovascular events, and COPD exacerbations. However, it is unclear if forced expiratory
volume in one second (FEV1) and forced vital capacity (FVC) differ in predictive value.
Patients and Methods: Data from 16,485 participants in the Study to Understand
Mortality and Morbidity (SUMMIT) in COPD were analyzed. Patients were grouped into
quintiles for each lung function parameter (FEV1 %predicted, FVC %predicted, FEV1/FVC).
The four highest quintiles (Q2–Q5) were compared to the lowest (Q1) to assess their
relationship with all-cause mortality, cardiovascular events, and moderate-to-severe and
severe exacerbations. Cox-regression was used, adjusted for age, sex, ethnicity, body-mass
index, smoking status, previous exacerbations, cardiovascular disease, treatment, and mod-
ified Medical Research Council dyspnea score.
Results: Compared to Q1 (<53.5% FEV1 predicted), increasing FEV1 quintiles (Q2 53.5–457.5%
predicted, Q3 57.5–461.6% predicted, Q4 61.6–465.8% predicted, and Q5 ≥65.8%) were all
associated with significantly decreased all-cause mortality (20% (4–34%), 28% (13–40%), 23%
(7–36%), and 30% (15–42%) risk reduction, respectively). In contrast, a significant risk reduction
(21% (4–35%)) was seen only between Q1 and Q5 quintiles of FVC. Neither FEV1 nor FVC was
associated with cardiovascular risk. Increased FEV1 and FEV1/FVC quintiles were also associated
with the reduction of moderate-to-severe and severe exacerbations while, surprisingly, the highest
FVC quintile was related to the heightened exacerbation risk (28% (8–52%) risk increase).
Conclusion: Our results suggest that FEV1 is a stronger predictor for all-cause mortality
than FVC in moderate COPD patients with heightened cardiovascular risk and that subjects
with moderate COPD have very different risks.
Keywords: airflow limitation, cardiovascular risk, exacerbation, lung function, lung
volumes, death rate
Introduction
Chronic obstructive pulmonary disease (COPD) is a common, progressive disorder
of the airways and lung parenchyma and is the fourth leading cause of death.1
Clinical variables that predict mortality are important for identifying patients at
highest risk and include lung function, exacerbation burden and comorbidities.1–4
Interestingly, when comparing mortality risk based purely on lung function and the
symptoms-exacerbation risk-based Global Initiative for Chronic Obstructive Lung
Disease (GOLD) 2013 COPD classification, lung function served as a better
predictor.5
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It has long been debated whether forced expiratory
volume in one second (FEV1) or forced vital capacity
(FVC) is the best physiological prognostic measure and
if the relationship between FEV1 and mortality is due to
airflow limitation or low lung volumes. Analyzing the
7489 participants in the general population in the
Atherosclerosis Risk in Communities study, Burney &
Hooper concluded that the overall mortality was more
strongly related to FVC than to FEV1;
6 this was supported
by a post hoc analysis of the Burden of Obstructive Lung
Disease study reporting that the national COPD related
mortality was more strongly associated with the preva-
lence of spirometric restriction than obstruction.7 In con-
trast, other analyses, such as the Normative Aging Study
concluded that FEV1 is more strongly related to mortality
than FVC in a general population.8
Cardiovascular disease (CVD) frequently accompanies
COPD.9,10 The close relationship is due to common etiol-
ogies (i.e., aging, smoking), increased systemic inflamma-
tion, hypoxemia, and increased pulmonary vascular
resistance.10 The interplay between CVD and COPD
increases the morbidity and mortality of each disorder.
For instance, it has been shown that coronary artery calci-
fication, a non-invasive marker for coronary artery disease
is associated with increased mortality in COPD.11
However, it is debated if established CVD is an indepen-
dent risk factor for COPD exacerbations.12,13 Regarding
cardiovascular mortality, a strong association has been
found with FVC,14 FEV1,
15–17 and the rate of lung func-
tion decline18 in population-based studies, suggesting that
cardiovascular morbidity may be a relevant factor when
investigating the relationship between lung function and
mortality. Finally, COPD exacerbations pose an increased
risk for cardiovascular events.19,20
Given the contrasting findings illustrated above, and
the need to risk stratify COPD patients with comorbid
CVD, we aimed to examine the prognostic value of the
spirometric indices by analyzing the data of the Study to
Understand Mortality and Morbidity in COPD (SUMMIT)
trial.
Patients and Methods
Study Design and Participants
The SUMMIT was a multicenter, randomized, double-
blind, parallel-group, placebo-controlled trial assessing
the effect of once-daily treatment with fluticasone furo-
ate/vilanterol (100/25 μg), fluticasone furoate (100 μg),
vilanterol (25 μg), or matched placebo on mortality in
patients with moderate COPD; i.e., FEV1 between 50%
and 70% of predicted value, and an increased cardiovas-
cular risk.21 For patients ≥40 years of age, this was defined
as any one of the following: established coronary artery
disease, established peripheral vascular disease, previous
stroke, previous myocardial infarction, or diabetes mellitus
with target organ disease. In addition, for patients ≥60
years of age, any one of the criteria applicable for patients
≥40 years of age or two of the following: being treated for
hypercholesterolemia, being treated for hypertension,
being treated for diabetes mellitus, or being treated for
peripheral vascular disease.21 The event-driven study
included 16,485 participants and lasted until at least 1000
deaths were recorded. There was no difference between
the four treatment arms for the primary outcome of all-
cause mortality.22
In this post hoc analysis of the SUMMIT study popula-
tion, we hypothesized that FVC may be a better predictor
of overall mortality and major cardiovascular events than
FEV1 and FEV1/FVC, whereas FEV1 and FEV1/FVC
would be stronger predictors of COPD exacerbations
than FVC.
Major cardiovascular events included cardiovascular
death, myocardial infarction, stroke, unstable angina, and
transient ischemic attack. We analyzed moderate to severe
and severe exacerbations separately. A moderate COPD
exacerbation was defined as an exacerbation treated with
antibiotics and/or systemic corticosteroids whereas
a severe COPD exacerbation required hospitalization.
All participants in the current analysis provided writ-
ten, informed consent for trial participation. The study was
conducted at 1373 sites in accordance with the Declaration
of Helsinki and Good Clinical Practice guidelines and was
approved by local ethics committees (Supplement 1). Trial
registration number: NCT01313676.
Lung Function Measurements
Post-bronchodilator spirometry has been performed
according to the European Respiratory Society/American
Thoracic Society guidelines.23 Prior to the spirometry
long-acting β-agonists and inhaled corticosteroids were
withheld for 48 hours, long-acting muscarinic antagonists
were withheld for 1 week. Patients with systemic steroid
use within 30 days were not included. Lung function
measurements at screening were repeated after a 4–10
days run-in period at the baseline visit.
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Statistical Analyses
For each measure (percent predicted FEV1, percent pre-
dicted FVC and FEV1/FVC ratio), participants were allo-
cated into lung function quintiles (Table 1). The number of
volunteers allocated in each quintile was compared
between the screening and baseline visit.
For primary analyses, lung function data at screening were
analyzed. Cox proportional hazards models were applied,
adjusted for age, sex, ethnicity, body mass index (BMI),
smoking status, previous COPD exacerbations, cardiovascu-
lar entry criteria, ischemic and vascular disease indicators,
treatment, and modified Medical Research Council (mMRC)
dyspnea score. For each outcome, the lowest quintile (Q1) for
each lung function measure was used as the reference. Data
are expressed as median (95% confidence interval).
Results
Distribution of Lung Function Data
In total, data of 16,485 participants of the intent-to-treat
analysis were investigated. Lung function data both at
screening and baseline were grouped into quintiles. When
comparing the number of patients allocated to each quintile
at screening and baseline (at randomization), respectively,
only 44%, 54%, and 54% of participants were grouped in the
same FEV1, FVC, and FEV1/FVC quintiles, illustrating the
variability in these spirometric indices (Table 2).
FEV1, FVC, and FEV1/FVC as Predictors
for All-Cause Mortality, Cardiovascular
Events, and COPD Exacerbations
Compared with patients with the lowest FEV1 (Q1,
<53.5% predicted), each of the higher quintiles was asso-
ciated with better survival, ranging from a 20% lower risk
in Q2 to a 30% lower risk in Q5 (Table 1, Figure 1).
Although there was a trend for decreasing mortality
along the increasing quintiles of FEV1/FVC (7.8%, 6.7%,
5.9%, 5.4%, and 5.9%, from Q1 to Q5), this did not reach
the level of significance. In contrast, for FVC only mor-
tality in quintile 5 (FVC≥87.6% predicted) differed sig-
nificantly from that of quintile 1 (FVC<67.4% predicted).
No lung function indices were predictive of a major car-
diovascular event.
Table 1 Association Between Lung Function Indices and Time to Mortality, Cardiovascular Events, Moderate and Severe
Exacerbations, and Severe Exacerbations
Time to Death
Risk Reduction
vs. Q1
Time to First
Major
Cardiovascular
Event
Risk Reduction
vs. Q1
Time to First Moderate/
Severe Exacerbation Risk
Reduction vs. Q1
Time to First
Severe
Exacerbation Risk
Reduction vs. Q1
FEV1% Predicted Q1 <53.5%
Q2 53.5 to 57.5% 20% (4 to 34%) 5% (−20 to 25%) 11% (3 to 19%) 10% (−5 to 23%)
Q3 57.5 to 61.6% 28% (13 to 40%) 15% (−8 to 33%) 15% (7 to 22%) 25% (12 to 37%)
Q4 61.6 to 65.8 23% (7 to 36%) 9% (−15 to 28%) 23% (16 to 30%) 37% (25 to 47%)
Q5 ≥65.8% 30% (15 to 42%) 7% (−18 to 26%) 27% (20 to 33%) 40% (28 to 49%)
FVC % Predicted Q1 <67.4%
Q2 67.4 to 73.6% 14% (−4 to 29%) 16% (−7 to 34%) 2% (−8 to 10%) 4% (−15 to 20%)
Q3 73.6 to 79.5% 11% (−8 to 27%) −4% (−30 to 17%) −4% (−14 to 5%) 0% (−20 to 17%)
Q4 79.5 to 87.6% 14% (−4 to 29%) 11% (−13 to 29%) −6% (−17 to 3%) −13% (−34 to 6%)
Q5 ≥87.6% 21% (4 to 35%) 21% (−1 to 38%) −22% (−34 to −11%) −28% (−52 to −8%)
FEV1/FVC Q1 <0.51
Q2 0.51 to 0.57 0% (−21 to 16%) −7% (−36 to 16%) 18% (11 to 25%) 22% (9 to 33%)
Q3 0.57 to 0.62 7% (−12 to 24%) −8% (−38 to 15%) 28% (22 to 35%) 39% (28 to 49%)
Q4 0.62 to 0.66 10% (−10 to 26%) −12% (−43 to 12%) 29% (22 to 35%) 41% (29 to 50%)
Q5 ≥0.66 −5% (−28 to 14%) −18% (−50 to 8%) 36% (30 to 42%) 48% (37 to 57%)
Notes: Results are from Cox Proportional Hazard models and are presented as risk reduction compared with Q1 quintile groups (with 95% confidence intervals). These are
calculated as (1–hazard ratio) × 100. Negative % reductions indicate increase in risk, i.e., hazard ratio >1. Nominally significant differences are presented in bold (p<0.05, no
adjustment for multiplicity).
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity.
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Compared with quintile 1, higher FEV1 and FEV1/FVC
quintiles were all associated with a reduction of risk of
moderate-to-severe and severe exacerbations (Table 1).
Unexpectedly, quintile 5 of FVC showed an increased risk
of a moderate-to-severe and severe exacerbation compared
to quintile 1. Despite analyzing FEV1 within a narrow range
(50–70%), there was a strong association between FEV1 and
exacerbation risk, with the lowest FEV1 quintile having
a 27% higher risk of moderate/severe exacerbations com-
pared with the highest FEV1 quintile (≥65.8%), and a 40%
increase for severe exacerbations.
Discussion
Analyzing the results of the SUMMIT trial, we found that
FEV1 was a better predictor for mortality and exacerbation
risk than FVC, while neither of them was associated with
the risk for major cardiovascular events. The clearer rela-
tionship between mortality and FEV1 than with FVC sug-
gests that airflow limitation, rather than lung volume,
predicts mortality in patients with COPD and heightened
cardiovascular risk.
Previous general population studies highlighted the
predictive role of FVC versus FEV1.
6,14 There are possible
explanations for the discrepancies. First, the current study
included only patients with an obstructive lung function
pattern.21 A restrictive pattern may also be common in the
general population and associated with poverty7 and mor-
bid obesity, which may both lead to increased mortality.24
Although our analysis was adjusted for BMI, socioeco-
nomic data were unavailable and several other variables,
Table 2 Distribution of Participants in Lung Function Quintiles at Screening and Baseline
FEV1 Screening
Q1: <53.5%
(N=3296)
Q2: ≥53.5 to
<57.5% (N=3297)
Q3: ≥57.5 to
<61.6% (N=3297)
Q4: ≥61.6 to
<65.6% (N=3297)
Q5: ≥65.6%
(N=3296)
BASELINE Q1: <52.3% (N=3296) 1844 858 350 178 65
Q2: ≥52.3 to <56.7%
(N=3297)
941 1167 741 311 137
Q3: ≥56.7 to <61.1%
(N=3297)
319 808 1109 732 329
Q4: ≥61.1 to <66.0%
(N=3297)
119 308 743 1235 892
Q5: ≥66.0% (N=3297) 73 156 354 841 1873
FVC Q1: <67.4%
(N=3296)
Q2: ≥67.4 to
<73.6% (N=3297)
Q3: ≥73.6 to
<79.5% (N=3297)
Q4: ≥79.5 to
<87.6% (N=3297)
Q5: ≥87.6%
(N=3297)
Q1: <52.3% (N=3296) 2173 702 264 113 44
Q2: ≥65.9 to <72.6%
(N=3297)
798 1412 739 266 82
Q3: ≥72.6 to <78.8%
(N=3297)
224 856 1357 690 170
Q4: ≥78.8 to <87.2%
(N=3297)
68 272 773 1548 635
Q5: ≥87.2% (N=3297) 33 55 164 680 2365
FEV1/FVC Q1: <0.51
(N=3296)
Q2: ≥0.51 to <0.57
(N=3297)
Q3: ≥0.57 to <0.62
(N=3297)
Q4: ≥0.62 to <0.66
(N=3296)
Q5: ≥0.66
(N=3297)
Q1: <0.51 (N=3296) 2480 610 122 37 33
Q2: ≥0.51 to <0.57
(N=3297)
609 1668 720 196 90
Q3: ≥0.57 to <0.62
(N=3297)
112 718 1428 757 269
Q4: ≥0.62 to <0.66
(N=3296)
52 181 716 1407 955
Q5: ≥0.66 (N=3297) 33 103 296 888 1935
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity.
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such as very severe heart failure (which may lead to
reduced FVC), were not included, which may have influ-
enced our findings. While inclusion into SUMMIT was not
restricted by FVC as it was for FEV1, we only included
patients with moderate COPD, which imposed some
restrictions on FVC indirectly. In this sense, the previously
seen association between reduced lung volumes and car-
diovascular outcomes may have been driven by subjects
with very low FVC.14
We found a steep gradient between FEV1 quintiles and
exacerbation risk. As the FEV1 cut-off value generally
applied for separating moderate from severe COPD is
quite arbitrary, our findings add to the increasing percep-
tion that, for usual clinical care, these arbitrary FEV1 cut-
off values hold little clinical value.
Our article also highlights the obscurity of lung func-
tion values from a single spirometry. Only approximately
half of the participants allocated to different lung function
quintiles at screening were grouped in the same quintile at
baseline. Indeed, approximately 1% of patients changed
from the lowest to highest quintiles or vice versa. This can
be likely explained by the methodological variability of
lung function measurements and physiological variability
of the airway caliber.
Our analysis has limitations. Only patients with mod-
erate COPD were included and a wider lung function
range would likely have provided more robust data. Lung
function aside, hypoxia, hypercapnia, BMI, dyspnea, and
exercise capacity are also strong predictors of mortality in
COPD.1 Although our analyses were adjusted for BMI and
mMRC dyspnea score, blood gas values and exercise
capacity test were not available in SUMMIT. However,
patients on long-term oxygen were excluded, as were
those with very severe heart failure, severe renal failure,
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Figure 1 Kaplan–Meier plot showing unadjusted relationship between FEV1% predicted at screening and all-cause mortality.
Abbreviations: FEV1, forced expiratory volume in one second; N, number of patients.
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or whose life expectancy from diseases other than vascular
disease and COPD was under 3 years. We therefore do not
believe that our findings are the result of confounding by
these other risk factors.
Confirming previous findings, lower FEV1 and FEV1
/FVC were associated with higher risk for COPD
exacerbations.13,25,26 Increased disease severity is asso-
ciated with heightened airway and systemic
inflammation.27 The ECLIPSE study highlighted the
potential role of persistent systemic inflammation leading
to frequent exacerbations.28 However, analyzing the
SUMMIT data, the levels of systemic inflammatory bio-
markers did not relate to the frequency of flare-ups.29
Interestingly we found that the highest FVC quintile was
associated with an increased exacerbation risk. This,
together with the gradually increased risk for exacerbation
with FEV1 decline suggest that more severe emphysema
may be related to higher number of exacerbations. This is
in line with the ECLIPSE study;25 however, no computed
tomography was performed in the SUMMIT trial. Our
results are similar to the findings of the TIOSPIR study
showing that larger FVC was associated with increased
exacerbation risk.12
Conclusion
In conclusion, we found strong relationships between FEV1
and exacerbation rate and all-cause mortality, but not with
major cardiovascular events, in SUMMIT. These were stron-
ger than for FVC and stronger than we anticipated for
patients with moderate COPD and a limited FEV1 range.
Abbreviations
BMI, body mass index; COPD, chronic obstructive pul-
monary disease; CVD, cardiovascular disease; FEV1,
forced expiratory volume in one second; FVC, forced
vital capacity; GOLD, Global Initiative for Chronic
Obstructive Lung Disease; mMRC, modified Medical
Research Council; SUMMIT, Study to Understand
Mortality and Morbidity.
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